Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375400 | 0.81 | BCHE (0.62) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL14376841 | 0.80 | BCHE (0.69) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL6171632 | 0.79 | HPGD (0.62) | BCHEKDM4EHPGDHTTALDH1A1 | |
| Bromide SCHEMBL10779800 | 0.79 | BCHE (0.76) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL13632370 | 0.79 | BCHE (0.56) | BCHEKDM4EHPGDHTTALDH1A1 | |
| Bromide SCHEMBL10776806 | 0.79 | BCHE (0.68) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL13923621 | 0.79 | HPGD (0.59) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL5342011 | 0.78 | HPGD (0.57) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL14350101 | 0.78 | BCHE (0.55) | BCHEKDM4EHPGDHTTALDH1A1 | |
| SCHEMBL19160266 | 0.78 | BCHE (0.79) | BCHEKDM4EHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | BCHE 4622/4885KDM4E 2688/4885HPGD 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.